BTIG lowered the firm’s price target on Zoetis (ZTS) to $160 from $200 and keeps a Buy rating on the shares. The company’s Q3 results missed on the top line and the management cut its guidance, the analyst tells investors in a research note. Zoetis’s U.S. bread-and-butter companion – animal health segment – came in flat, and below the firm’s 6% expected growth rate, as the company cited a step-up in competitive activity on top of the 2% decline in vet clinic visits, BTIG added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis price target lowered to $175 from $211 at Morgan Stanley
- Zoetis price target lowered to $190 from $215 at Piper Sandler
- Elanco price target raised to $27 from $23 at Stifel
- Zoetis: A Strong Buy Amidst Challenges with Promising Growth Potential
- Zoetis price target lowered to $141 from $158 at UBS